Homepage>Company>Media>Pharma News>2019>Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer